Among advanced non-small-cell lung cancer (NSCLC) patients, epidermal growth factor receptor (EGFR) T790M mutation is the most common mechanism which results in approximately 60% of acquired resistance to first generation tyrosine kinase inhibitors (TKIs). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.